Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
Open Access
- 6 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 250-256
- https://doi.org/10.1016/j.jcf.2020.11.002
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 16 references indexed in Scilit:
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleThe New England Journal of Medicine, 2019
- Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508delMolecular Pharmacology, 2018
- New and emerging targeted therapies for cystic fibrosisBMJ, 2016
- Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry DataAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRThe New England Journal of Medicine, 2015
- Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctorsPediatric Pulmonology, 2015
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Cystic fibrosisThe Lancet, 2009
- Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus ReportThe Journal of Pediatrics, 2008
- Evidence for airway surface dehydration as the initiating event in CF airway diseaseJournal of Internal Medicine, 2007